CN108866004A - Shp-1敲除的t细胞及其构建方法 - Google Patents
Shp-1敲除的t细胞及其构建方法 Download PDFInfo
- Publication number
- CN108866004A CN108866004A CN201810665548.6A CN201810665548A CN108866004A CN 108866004 A CN108866004 A CN 108866004A CN 201810665548 A CN201810665548 A CN 201810665548A CN 108866004 A CN108866004 A CN 108866004A
- Authority
- CN
- China
- Prior art keywords
- cell
- car
- shp
- gene
- sgrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 82
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 title claims abstract description 48
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 title claims abstract description 27
- 238000010276 construction Methods 0.000 title claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 41
- 108091033409 CRISPR Proteins 0.000 claims description 28
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 11
- 230000002147 killing effect Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000008685 targeting Effects 0.000 claims description 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 7
- 101150029707 ERBB2 gene Proteins 0.000 claims description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 7
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 7
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 7
- 102100025096 Mesothelin Human genes 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 108010085220 Multiprotein Complexes Proteins 0.000 claims description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 230000000903 blocking effect Effects 0.000 abstract description 8
- 238000009169 immunotherapy Methods 0.000 abstract description 2
- 230000001665 lethal effect Effects 0.000 abstract description 2
- 230000005611 electricity Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 15
- 230000006872 improvement Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 230000022534 cell killing Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 4
- 101150058049 car gene Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000007480 sanger sequencing Methods 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012815 AlphaLISA Methods 0.000 description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 description 2
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 101150005990 SHP1 gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/10—Vectors comprising a non-peptidic targeting moiety
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810665548.6A CN108866004A (zh) | 2018-06-26 | 2018-06-26 | Shp-1敲除的t细胞及其构建方法 |
| PCT/CN2018/095635 WO2020000526A1 (fr) | 2018-06-26 | 2018-07-13 | Lymphocyte t shp-1-inactivé et procédé de construction associé |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810665548.6A CN108866004A (zh) | 2018-06-26 | 2018-06-26 | Shp-1敲除的t细胞及其构建方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108866004A true CN108866004A (zh) | 2018-11-23 |
Family
ID=64294683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810665548.6A Pending CN108866004A (zh) | 2018-06-26 | 2018-06-26 | Shp-1敲除的t细胞及其构建方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108866004A (fr) |
| WO (1) | WO2020000526A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116334077A (zh) * | 2022-07-29 | 2023-06-27 | 江苏省人民医院（南京医科大学第一附属医院） | 一种气道上皮细胞shp-1基因特异性敲除小鼠模型的构建方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107109421A (zh) * | 2014-10-09 | 2017-08-29 | 国立大学法人山口大学 | Car表达载体及car表达t细胞 |
| CN107164407A (zh) * | 2017-07-04 | 2017-09-15 | 王小平 | 无物种限制的真核生物同时进行基因敲除和基因过表达 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015142675A2 (fr) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Traitement du cancer au moyen d'un récepteur antigénique chimérique |
| EP3800248A3 (fr) * | 2014-04-18 | 2021-08-04 | Editas Medicine, Inc. | Méthodes, compositions et constituants associés à crispr/cas pour l'immunothérapie du cancer |
| US20180112213A1 (en) * | 2015-03-25 | 2018-04-26 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
-
2018
- 2018-06-26 CN CN201810665548.6A patent/CN108866004A/zh active Pending
- 2018-07-13 WO PCT/CN2018/095635 patent/WO2020000526A1/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107109421A (zh) * | 2014-10-09 | 2017-08-29 | 国立大学法人山口大学 | Car表达载体及car表达t细胞 |
| CN107164407A (zh) * | 2017-07-04 | 2017-09-15 | 王小平 | 无物种限制的真核生物同时进行基因敲除和基因过表达 |
Non-Patent Citations (1)
| Title |
|---|
| INGUNN M.STROMNES等: "Abrogation of SHP-1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo", 《J IMMUNOL.》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116334077A (zh) * | 2022-07-29 | 2023-06-27 | 江苏省人民医院（南京医科大学第一附属医院） | 一种气道上皮细胞shp-1基因特异性敲除小鼠模型的构建方法及其应用 |
| CN116334077B (zh) * | 2022-07-29 | 2024-02-02 | 江苏省人民医院（南京医科大学第一附属医院） | 一种气道上皮细胞shp-1基因特异性敲除小鼠模型的构建方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020000526A1 (fr) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Solomon et al. | Cohesin gene mutations in tumorigenesis: from discovery to clinical significance | |
| US20200317777A1 (en) | Enhanced chimeric antigen receptors and uses thereof | |
| CN106399306B (zh) | 靶向人lncRNA-UCA1抑制膀胱癌的sgRNA、基因载体及其应用 | |
| CN109715803A (zh) | 等位基因编辑及其应用 | |
| AU2018342245A1 (en) | Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation | |
| CN109517820A (zh) | 一种靶向HPK1的gRNA以及HPK1基因编辑方法 | |
| Zhang et al. | Downstream class switching leads to IgE antibody production by B lymphocytes lacking IgM switch regions | |
| Solé et al. | AT follicular helper cell origin for T regulatory type 1 cells | |
| CN115697356A (zh) | 通过抑制carm1治疗癌症的方法 | |
| CN108866004A (zh) | Shp-1敲除的t细胞及其构建方法 | |
| US20210015866A1 (en) | Tissue resident memory cell profiles, and uses thereof | |
| CN110172089A (zh) | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 | |
| EP2039766A1 (fr) | Cellule immunocompetente presentant un anticorps anti-cd38 sur sa surface | |
| WO2019036043A2 (fr) | Procédé de génération d'un cocktail de vaccins anticancéreux personnalisés à partir de modifications génétiques dérivées de tumeur pour le traitement du cancer | |
| Kwok et al. | Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens | |
| WO2011097618A1 (fr) | Inhibition d'adn méthyltransférases de novo favorisant la multiplication de cellules souches hématopoïétiques normales | |
| EP4376858A1 (fr) | Compositions et méthodes pour améliorer la persistance et la fonction des lymphocytes t | |
| Dikiy et al. | Terminal differentiation and persistence of effector regulatory T cells essential for the prevention of intestinal inflammation | |
| CN107082811B (zh) | 一种嵌合抗原受体并融合诱导性凋亡酶的复合蛋白 | |
| Wang et al. | High recallability of memory B cells requires ZFP318-dependent transcriptional regulation of mitochondrial function | |
| CN117866906B (zh) | Foxr1抑制剂在制备用于治疗肿瘤的药物中的应用 | |
| Peeters et al. | Increased EZH2 function in regulatory T cells promotes their capacity to suppress autoimmunity by driving effector differentiation prior to activation | |
| Zahedimaram | The identification of the mechanisms of lrba deficiency dependent defects in regulatory t-cell function | |
| EP3635098B1 (fr) | Lymphocytes t modifiés pour surexprimer lephf19 | |
| US20240091259A1 (en) | Generation of anti-tumor t cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181123 |
|
| RJ01 | Rejection of invention patent application after publication |